Retinoblastoma Expression in Thyroid Neoplasms

[1]  C. Portwine,et al.  The genetics of childhood cancer. , 2002, European journal of cancer.

[2]  B. Gallie,et al.  Cumulative Effect of Phosphorylation of pRB on Regulation of E2F Activity , 1999, Molecular and Cellular Biology.

[3]  P. Branton,et al.  RBP1 induces growth arrest by repression of E2F-dependent transcription , 1999, Oncogene.

[4]  B. Czerniak,et al.  Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer , 1999, Oncogene.

[5]  E. Rubin,et al.  Protein phosphatase type 1, the product of the retinoblastoma susceptibility gene, and cell cycle control. , 1998, Frontiers in bioscience : a journal and virtual library.

[6]  T. Jacks,et al.  Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/−) mice , 1998, Nature Genetics.

[7]  K. Kashima,et al.  Cytoplasmic biotin-like activity interferes with immunohistochemical analysis of thyroid lesions: a comparison of antigen retrieval methods. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[8]  A. El‐Naggar,et al.  Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications. , 1997, The American journal of pathology.

[9]  V P Collins,et al.  Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. , 1996, Oncogene.

[10]  R. Kratzke,et al.  Wild-type and mutant retinoblastoma protein in paraffin sections. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[11]  R. Lotan,et al.  Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. , 1995, The American journal of pathology.

[12]  L. Donehower,et al.  Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. , 1995, Cancer research.

[13]  W. Benedict,et al.  Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti‐RB antibodies , 1994, International journal of cancer.

[14]  P. Soares,et al.  Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid , 1994, Histopathology.

[15]  J. Nesland,et al.  Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland , 1994, The Journal of pathology.

[16]  K. Helin,et al.  Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein , 1993, Molecular and cellular biology.

[17]  S. Harlow,et al.  Diagnostic utility of DNA content flow cytometry in follicular neoplasms of the thyroid , 1992, Journal of surgical oncology.

[18]  J. Figge,et al.  Image analysis quantitation of immunoreactive retinoblastoma protein in human thyroid neoplasms with a streptavidin-biotin-peroxidase staining technique. , 1991, The American journal of pathology.

[19]  W. Benedict,et al.  Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level. , 1991, Oncogene.

[20]  G E Moore,et al.  Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. , 1991, Cancer research.

[21]  C. Cordon-Cardo,et al.  Altered expression of the retinoblastoma gene product in human sarcomas. , 1990, The New England journal of medicine.

[22]  S. Rubin,et al.  Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. , 1990, Molecular endocrinology.

[23]  W. Lee,et al.  Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Moses,et al.  Oncogenes and growth factors in thyroid carcinogenesis. , 1990, Endocrinology and metabolism clinics of North America.

[25]  R. Weinberg,et al.  Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[26]  W. Lee,et al.  Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. , 1990, Science.

[27]  F. Wyllie,et al.  Structure and expression of nuclear oncogenes in multi-stage thyroid tumorigenesis. , 1989, British Journal of Cancer.

[28]  W. J. Brammar,et al.  The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. , 1989, Oncogene.

[29]  N. Lemoine,et al.  High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. , 1989, Oncogene.

[30]  P. L. Chen,et al.  Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. , 1988, Science.

[31]  J. Lillehaug,et al.  Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB. , 1988, British Journal of Cancer.

[32]  Wen-Hwa Lee,et al.  The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity , 1987, Nature.

[33]  B. Ducatman,et al.  Hürthle cell lesions in the thyroid. , 1987, American journal of clinical pathology.

[34]  H. Fox,et al.  Antifungal Chemotherapy , 1980 .

[35]  W. W. Nichols,et al.  Chromosomal deletion and retinoblastoma. , 1976, The New England journal of medicine.

[36]  A. Knudson,et al.  Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Knudson.  The genetics of childhood cancer , 1975, Cancer.

[38]  K. Gabriel,et al.  Simultaneous Test Procedures for Multiple Comparisons on Categorical Data , 1966 .

[39]  M. Merino,et al.  Worrisome histologic alterations following fine-needle aspiration of the thyroid (WHAFFT). , 1994, Pathology annual.

[40]  P. D. Lewis.  Surgical Pathology of the Thyroid , 1993 .

[41]  W. Lee,et al.  Antibodies detecting abnormalities of the retinoblastoma susceptibility gene product (pp110RB) in osteosarcomas and synovial sarcomas. , 1989, Oncogene research.

[42]  M. Merino,et al.  Histopathologic differential diagnosis of the thyroid. , 1981, Pathology annual.